|
Evolus Inc (NASDAQ: EOLS) |
|
Evolus Inc
EOLS's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Looking into Evolus Inc growth rates, revenue grew
by 22.12 % in III. Quarter 2024 from the same quarter a year ago.
Ranking at No. 969
Major Pharmaceutical Preparations industry recorded
growth of revenues by 9.73 %
Evolus Inc net loss increased from $-17 millions, to $-19 millions in III. Quarter 2024,
• More on EOLS's Growth
|
|
Evolus Inc realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 16.51 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 3.08.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.16.
• More on EOLS's Valuation
|
|
|
|
|
Evolus Inc realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 16.51 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 3.08.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.16.
Evolus Inc Price to Book Ratio is at 129.94 higher than Industry Avg. of 79.2, and higher than S&P 500 Avg. of 0.01
• More on EOLS's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2024 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com